Abstract 67P
Background
One way to significantly reduce the incidence of systemic side effects of antitumoral immunotherapeutics is intratumoral gene-immune therapy. The use of non-viral systems is attractive for gene therapy due to low immunogenicity of the carrier, low production costs, and relatively high capacity. Thus, non-viral intratumoral gene-immune therapy is a promising area for development of antitumor drugs. OX40 and 4-1BB T cell co-stimulators are popular targets in immunotherapeutic drug development, but currently there are no approved drugs targeting these receptors. We suppose that the natural ligands of these receptors, OX40L and 4-1BBL, would be effective in non-viral gene-immune therapeutics.
Methods
The antitumor effect of stable OX40L or 4-1BBL expression by inoculated cancer cells on CT26 tumor growth was studied. CT26 cell lines stably expressing OX40L or 4-1BBL were obtained, tumor graftability and growth in BALB/c mice were evaluated. Next, antitumor effect of non-viral gene-immune therapy with OX40L or 4-1BBL was studied, complexes of polymeric carrier with plasmid DNA encoding OX40L or 4-1BBL were prepared and injected three times into CT26wt subcutaneous tumors in BALB/c mice, starting when tumors reached 50±15 mm3 .
Results
Stable expression of OX40L and 4-1BBL significantly suppressed CT26 tumor growth, delayed tumor resorption was observed in the experimental groups. The use of OX40L and 4-1BBL in the context of gene-immune therapy had a significant effect on CT26 tumor growth – median animal survival compared to the control group was increased by 26.5% (OX40L) and 41.2% (4-1BBL), life expectancy was increased by 24% (OX40L) and 24.5% (4-1BBL), tumor growth inhibition 10 days after treatment was 70% (OX40L) and 71.3% (4-1BBL). No visible immune-related adverse events (irAEs) were observed.
Conclusions
OX40L and 4-1BBL have a comparable potent antitumoral effect on CT26 tumor growth in the context of non-viral gene-immune therapy, and such therapeutic approach does not yield visible systemic irAEs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Group of Gene Immuno Oncotherapy, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry.
Funding
This study was supported by RSF grant 22-25-00806, https://rscf.ru/project/22-25-00806/.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09